Objectiu de la convocatòria

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe's growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.

Característiques principals

The Call has the following topics:

Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodiesDiabetic kidney disease biomarkers (DKD-BM)Inflammation and AD: modulating microglia function – focussing on TREM2 and CD33Understanding the role of amyloid imaging biomarkers in the current and future diagnosis and management of patients across the spectrum of cognitive impairment (from pre-dementia to dementia)Evolving models of patient engagement and access for earlier identification of Alzheimer's disease: phased expansion studyFrom ApoE biology to validated Alzheimer's disease targets

This Call is being run in a two stage submission and evaluation process.

Short proposals for this call can only be done through the IMI SOFIA software tool: https://sofia.imi.europa.eu/Pages/Login.aspx?ReturnUrl=%2fPages%2fDefault.aspx

Convocatòria (URL)

http://www.imi.europa.eu/content/stage-1-16

Dotació

IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.

The EU contribution is:

Topic 1: 6.000.000 EUR

Topic 2: 15.086.000 EUR

Topic 3: 8.838.000 EUR

Topic 4: 12.000.000 EUR

Topic 5: 2.043.000 EUR

Topic 6: 3.510.000 EUR